WST (STOCKS)
West Pharmaceutical Services, Inc.
$259.960000
+3.410000 (+1.33%)
Prev close: $256.550000
Company Information
- Exchange
- XNYS
- Sector
- Health Technology
- Industry
- Medical Specialties
- CEO
- Eric Mark Green
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $18,721.27M
- Employees
- 10,600
- P/E (TTM)
- 37.78
- P/B (TTM)
- 5.82
- Dividend Yield
- 33.52%
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
12
Buy
5
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$2.04 | $1.85 | +0.1894 | +10.23% |
|
Sep 2025 (Q3)
|
$1.96 | $1.70 | +0.2616 | +15.40% |
|
Jun 2025 (Q2)
|
$1.84 | $1.52 | +0.3153 | +20.68% |
|
Mar 2025 (Q1)
|
$1.45 | $1.25 | +0.2043 | +16.40% |
Financial Statements
| Revenues | $3.07B |
| Benefits Costs and Expenses | $2.47B |
| Cost Of Revenue | $1.97B |
| Costs And Expenses | $2.47B |
| Gross Profit | $1.10B |
| Operating Expenses | $519.10M |
| Selling, General, and Administrative Expenses | $393.60M |
| Research and Development | $74.30M |
| Other Operating Expenses | $51.20M |
| Operating Income/Loss | $584.90M |
| Income/Loss Before Equity Method Investments | $600.90M |
| Income/Loss From Continuing Operations After Tax | $479.30M |
| Income/Loss From Continuing Operations Before Tax | $600.90M |
| Income/Loss From Equity Method Investments | $14.40M |
| Income Tax Expense/Benefit | $121.60M |
| Income Tax Expense/Benefit, Current | $135.30M |
| Income Tax Expense/Benefit, Deferred | -$13.70M |
| Net Income/Loss | $493.70M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $493.70M |
| Net Income/Loss Available To Common Stockholders, Basic | $493.70M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $6.83 |
| Diluted Earnings Per Share | $6.79 |
| Basic Average Shares | 72,300,000 |
| Diluted Average Shares | 72,700,000 |
| Assets | $4.27B |
| Current Assets | $1.98B |
| Inventory | $443.90M |
| Other Current Assets | $1.53B |
| Noncurrent Assets | $2.29B |
| Fixed Assets | $1.73B |
| Intangible Assets | $7.70M |
| Other Non-current Assets | $557.70M |
| Liabilities | $1.09B |
| Current Liabilities | $654.90M |
| Accounts Payable | $253.70M |
| Other Current Liabilities | $401.20M |
| Noncurrent Liabilities | $439.10M |
| Long-term Debt | $202.80M |
| Other Non-current Liabilities | $236.30M |
| Equity | $3.18B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $3.18B |
| Liabilities And Equity | $4.27B |
| Net Cash Flow From Operating Activities | $754.80M |
| Net Cash Flow From Operating Activities, Continuing | $754.80M |
| Net Cash Flow From Investing Activities | -$285.90M |
| Net Cash Flow From Investing Activities, Continuing | -$285.90M |
| Net Cash Flow From Financing Activities | -$185.10M |
| Net Cash Flow From Financing Activities, Continuing | -$185.10M |
| Exchange Gains/Losses | $22.90M |
| Net Cash Flow | $306.70M |
| Net Cash Flow, Continuing | $283.80M |
| Comprehensive Income/Loss | $646.30M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $646.30M |
| Other Comprehensive Income/Loss | $646.30M |
| Other Comprehensive Income/Loss Attributable To Parent | $152.60M |